SCHEMBL4813567

SCHEMBL4813567

CC1(C)C[CH]N(C(=O)c2ccc(-c3ccccc3)cc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.48
MAPK1 P28482 2/20 0.47
HPGD P15428 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
FASN P49327 5/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
MAPT P10636 2/20 0.43
SLC6A7 Q99884 1/20 0.43
TSHR P16473 2/20 0.43
LMNA P02545 1/20 0.43
ALDH1A1 P00352 1/20 0.41
RAB9A P51151 1/20 0.40
USP2 O75604 1/20 0.40
TP53 P04637 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HIF1A Q16665 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4818095 0.91 MAPK1 (0.43) MAPK1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL4814546 0.79 TSHR (0.50) HPGDMEN1KMT2AMAPTTSHR
SCHEMBL4813560 0.74 MAPK1 (0.61) POLBMAPK1HPGDMEN1KMT2A
SCHEMBL4815801 0.74 F7 (0.46) MAPK1HPGDMEN1KMT2ATSHR
SCHEMBL8163271 0.73 MAPK1 (0.60) POLBMAPK1HPGDMEN1KMT2A
SCHEMBL4817499 0.72 KMT2A (0.59) HPGDMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4815472 0.71 HPGD (0.52) POLBMAPK1HPGDMEN1KMT2A
SCHEMBL4819128 0.71 ALDH1A1 (0.46) POLBKMT2AMAPTTSHRALDH1A1
SCHEMBL3459574 0.70 HPGD (0.60) POLBMAPK1HPGDMEN1KMT2A
SCHEMBL8150817 0.68 FASN (0.67) POLBMAPK1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402606-B2 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss SMITHKLINE BEECHAM CORPORATION (US) 2008-07-22 US claimed
EP-1494663-A1 DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS SmithKline Beecham Corporation (US) 2005-01-12 EP claimed
WO-2003086385-A1 DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS SMITHKLINE BEECHAM CORPORATION (US) 2003-10-23 WO claimed
US-7402606-B2 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss SMITHKLINE BEECHAM CORPORATION (US) 2008-07-22 US disclosed